ISRCTN48334111 https://doi.org/10.1186/ISRCTN48334111

Randomised, Double-Blind, Placebo Controlled, Cross Over Trial of a Parenteral Modified Cobratoxin in Adrenomyeloneuropathy

Submission date
04/01/2005

Recruitment status
No longer recruiting

Registration date
10/03/2005

Overall study status
Completed

Last Edited
17/11/2010

Condition category
Nervous System Diseases

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[X] Results
[ ] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Phillip Lee

Contact details
National Hospital for Neurology and Neurosurgery
Queens Square
London
United Kingdom
WC1N 3BG

Additional identifiers

Protocol serial number
AMN002

Study information

Scientific Title

Acronym

MCTX in Adrenomyeloneuropathy

Study objectives
Not provided at time of registration.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration.

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Not Specified

Health condition(s) or problem(s) studied
Adrenomyeloneuropathy (AMN)

Interventions
Modified cobratoxin (0.25 mg) administered subcutaneously (sc) twice daily for 6 months versus placebo injections.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Not provided at time of registration.

Key secondary outcome(s)
Not provided at time of registration.

Completion date
10/03/2003

Eligibility

Key inclusion criteria
1. Male or female age ≥18 years
2. Diagnosis of AMN either biochemically or genetically
3. Have some motor disability that affects their gait
4. Willing and able to provide written informed consent
5. Willing and able to comply with study procedures

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 Years

Sex
All

Key exclusion criteria
Not provided at time of registration.

Date of first enrolment
10/03/2000

Date of final enrolment
10/03/2003

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
National Hospital for Neurology and Neurosurgery
London
United Kingdom
WC1N 3BG

Sponsor information

Organisation
ReceptoPharm Inc. (USA)

Funder(s)

Funder type
Industry

Funder Name
ReceptoPharm Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	26/08/2003		Yes	No